Invesco’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.12M | Buy |
247,925
+671
| +0.3% | +$2.93K | ﹤0.01% | 2812 |
|
|
2025
Q4 | $1.19M | Buy |
247,254
+37,616
| +18% | +$169K | ﹤0.01% | 2839 |
|
|
2025
Q3 | $952K | Buy |
209,638
+28,554
| +16% | +$105K | ﹤0.01% | 2959 |
|
|
2025
Q2 | $560K | Buy |
181,084
+41,622
| +30% | +$138K | ﹤0.01% | 3110 |
|
|
2025
Q1 | $487K | Buy |
139,462
+69,631
| +100% | +$232K | ﹤0.01% | 3160 |
|
|
2024
Q4 | $228K | Buy |
69,831
+3,780
| +6% | +$13.9K | ﹤0.01% | 3494 |
|
|
2024
Q3 | $254K | Buy |
66,051
+4,924
| +8% | +$18.9K | ﹤0.01% | 3463 |
|
|
2024
Q2 | $189K | Buy |
61,127
+1,589
| +3% | +$4.77K | ﹤0.01% | 3637 |
|
|
2024
Q1 | $154K | Buy |
59,538
+2,865
| +5% | +$7.42K | ﹤0.01% | 3692 |
|
|
2023
Q4 | $142K | Buy |
56,673
+58
| +0.1% | +$114 | ﹤0.01% | 3630 |
|
|
2023
Q3 | $115K | Buy |
56,615
+3,075
| +6% | +$6.45K | ﹤0.01% | 3699 |
|
|
2023
Q2 | $123K | Buy |
53,540
+6,585
| +14% | +$17.1K | ﹤0.01% | 3690 |
|
|
2023
Q1 | $142K | Buy |
46,955
+1,596
| +4% | +$4.5K | ﹤0.01% | 3674 |
|
|
2022
Q4 | $106K | Buy |
45,359
+7,394
| +19% | +$17.7K | ﹤0.01% | 3813 |
|
|
2022
Q3 | $72K | Buy |
37,965
+2,925
| +8% | +$6.89K | ﹤0.01% | 3880 |
|
|
2022
Q2 | $95K | Buy |
35,040
+8,142
| +30% | +$20.8K | ﹤0.01% | 3896 |
|
|
2022
Q1 | $80K | Buy |
26,898
+1,513
| +6% | +$4.63K | ﹤0.01% | 3886 |
|
|
2021
Q4 | $99K | Sell |
25,385
-3,795
| -13% | -$14.7K | ﹤0.01% | 3906 |
|
|
2021
Q3 | $126K | Buy |
29,180
+3,994
| +16% | +$13.3K | ﹤0.01% | 3897 |
|
|
2021
Q2 | $76K | Buy |
+25,186
| New | +$78K | ﹤0.01% | 3922 |
|
|
2018
Q1 | – | Sell |
-117,321
| Closed | -$592K | – | 3708 |
|
|
2017
Q4 | $592K | Buy |
117,321
+4,394
| +4% | +$25.8K | ﹤0.01% | 3229 |
|
|
2017
Q3 | $700K | Buy |
112,927
+14,837
| +15% | +$63.5K | ﹤0.01% | 3179 |
|
|
2017
Q2 | $353K | Sell |
98,090
-710
| -0.7% | -$2.44K | ﹤0.01% | 3432 |
|
|
2017
Q1 | $321K | Buy |
+98,800
| New | +$274K | ﹤0.01% | 3485 |
|
|
2015
Q3 | – | Sell |
-430,408
| Closed | -$5.1M | – | 3780 |
|
|
2015
Q2 | $5.1M | Buy |
430,408
+125,642
| +41% | +$1.91M | ﹤0.01% | 1970 |
|
|
2015
Q1 | $5.32M | Buy |
304,766
+301,311
| +8,721% | +$6.17M | ﹤0.01% | 1931 |
|
|
2014
Q4 | $52K | Sell |
3,455
-3,476
| -50% | -$60K | ﹤0.01% | 3904 |
|
|
2014
Q3 | $147K | Sell |
6,931
-227
| -3% | -$3.71K | ﹤0.01% | 3769 |
|
|
2014
Q2 | $93K | Buy |
+7,158
| New | +$101K | ﹤0.01% | 3912 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Invesco's ABUS Position: Q1 2026 in Review
Invesco increased its Arbutus Biopharma (ABUS) stake by 0.27% in Q1 2026, buying an estimated $2.93K and bringing the position to 247,925 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2812.
Invesco first reported a position in ABUS in Q2 2014 and has held it in 29 quarters since. The position peaked at $5.32M in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Invesco held 247,925 shares of Arbutus Biopharma worth $1.12M as of Q1 2026.
- Invesco bought 671 Arbutus Biopharma shares in Q1 2026, an estimated $2.93K.
- Arbutus Biopharma made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2812 holding.
- Invesco first reported a position in Arbutus Biopharma in Q2 2014 and has held it in 29 quarters since.
- Invesco's Arbutus Biopharma position peaked at $5.32M in Q1 2015.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.